Kidney allograft survival after acute rejection, the value of follow-up biopsies

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2334-2341

  El Ters, M ^a   Grande, J P ^a   Keddis, M T ^a   Rodrigo, E ^a   Chopra, B ^a   Dean, P G ^a   Stegall, M D ^a   Cosio, F G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute rejection; graft histology; graft survival; protocol biopsies

Indexed keywords

ALEMTUZUMAB; ANTIBODY; CD25 ANTIBODY; CYCLOSPORIN; DONOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ACUTE REJECTION; GRAFT HISTOLOGY; GRAFT SURVIVAL; PROTOCOL BIOPSIES;

ADULT; AGED; ALLOGRAFTS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 84883456555     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12370     Document Type: Article

References (37)

1. Sollinger HW., Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study G. A blinded, randomized clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
3. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM., Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993; 7: 345-352.
4. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-757.
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
6. Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P., Absence of deleterious effect of long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739-1743.
7. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5: 2473-2478.
8. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
9. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD., Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
10. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 9: 2124-2132.
11. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
12. Gago M, Cornell LD, Kremers WK, Stegall MD, Cosio FG., Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012. 12: 1199-1207.
13. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
14. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF., Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
15. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C., Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
16. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. AJT 2010; 10: 2223-2230.
17. Cosio FG, Lager DJ, Lorenz EC, Amer H, Gloor JM, Stegall MD., Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89: 1088-1094.
18. Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am SocNephrol 1993; 4: 1159-1171.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
20. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
21. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
22. Drachenberg CB, Papadimitriou JC, Ramos E., Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: A shifting paradigm ? Clin J Am Soc Nephrol 2006; 1: 374-379.
23. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7: 356-365.
24. Gloor J, Cosio F, Lager DJ, Stegall MD., The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373.
25. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant 2012; 12: 191-201.
26. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563-570.
27. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
28. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
29. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93: 41-46.
30. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
31. Cosio FG, Gloor JM, Sethi S, Stegall MD., Transplant glomerulopathy. Am J Transplant 2008; 8: 492-496.
32. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
33. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
34. Cosio FG, Roche Z, Agarwal A, Falkenhain ME, Sedmak DD, Ferguson RM., Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28: 752-758.
35. Baid-Agrawal S, Farris AB III, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
36. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681-685.
37. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.